Cargando…

Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease

Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Mi Jin, Choe, Yon Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2013
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760698/ https://www.ncbi.nlm.nih.gov/pubmed/24010109 http://dx.doi.org/10.5223/pghn.2013.16.2.65

Ejemplares similares

Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
por: Chun, Ji Young, et al.
Publicado: (2013)

Successful Azathioprine Treatment with Metabolite Monitoring in a Pediatric Inflammatory Bowel Disease Patient Homozygous for TPMT(*)3C
por: Lee, Mi-Na, et al.
Publicado: (2013)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Monitoring Thiopurine Metabolites in Korean Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Mi Jin, et al.
Publicado: (2014)

Azathioprine in inflammatory bowel disease, a safe alternative?
por: Tanis, A A
Publicado: (1998)

Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo
por: Turbayne, Alexander Keith, et al.
Publicado: (2022)

Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases
por: van Liere, Elsa L. S. A., et al.
Publicado: (2021)

Rheumatological manifestations in inflammatory bowel disease
por: Voulgari, Paraskevi V.
Publicado: (2011)

The history of genetics in inflammatory bowel disease
por: Ek, Weronica E., et al.
Publicado: (2014)

The use of ultrasound in inflammatory bowel disease
por: Kucharzik, Torsten, et al.
Publicado: (2017)

Manipulating bone disease in inflammatory bowel disease patients
por: Miheller, Pal, et al.
Publicado: (2013)

Endocrine and metabolic manifestations in inflammatory bowel disease
por: Tigas, Stelios, et al.
Publicado: (2012)

Familial and ethnic risk in inflammatory bowel disease
por: Santos, Maria Pia Costa, et al.
Publicado: (2018)

Role of bile acids in inflammatory bowel disease
por: Tiratterra, Elisa, et al.
Publicado: (2018)

Bile Acid Signaling in Inflammatory Bowel Diseases
por: Fiorucci, Stefano, et al.
Publicado: (2020)

Psychological factors associated with inflammatory bowel disease
por: Eugenicos, M P, et al.
Publicado: (2021)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Electrolyte and acid-base disorders in inflammatory bowel disease
por: Barkas, Fotis, et al.
Publicado: (2013)

An overview of lipid abnormalities in patients with inflammatory bowel disease
por: Agouridis, Aris P., et al.
Publicado: (2011)

Clostridium difficile infection in patients with inflammatory bowel disease
por: Saidel-Odes, Lisa, et al.
Publicado: (2011)

Management of cutaneous disorders related to inflammatory bowel disease
por: Pellicer, Zaira, et al.
Publicado: (2012)

Epidemiology of intrafamilial inflammatory bowel disease throughout Europe
por: Arias-Loste, Maria Teresa, et al.
Publicado: (2012)

Diagnosis and treatment of anemia in patients with inflammatory bowel disease
por: Mücke, Victoria, et al.
Publicado: (2017)

Advances in the development of new biologics in inflammatory bowel disease
por: Ungar, Bella, et al.
Publicado: (2016)

Treatment of Pyoderma Gangrenosum in Pediatric Inflammatory Bowel Disease
por: Vaidy, Katherine, et al.
Publicado: (2020)

The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021
por: Skamnelos, Alexandros, et al.
Publicado: (2021)

Long‐term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real‐world experience
por: Yewale, Rohan V, et al.
Publicado: (2023)

Update on current applications of proteomic in the study of inflammatory bowel disease
por: Roda, Giulia, et al.
Publicado: (2012)

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2016)

Adipokines and the role of visceral adipose tissue in inflammatory bowel disease
por: Karrasch, Thomas, et al.
Publicado: (2016)

Diagnosis and natural history of preclinical and early inflammatory bowel disease
por: Rodríguez-Lago, Iago, et al.
Publicado: (2020)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines
por: Hernández, Vicent, et al.
Publicado: (2012)

Telenutrition for Inflammatory Bowel Disease: A Tipping Point for Dietary Wellness
por: Elamin, Sami, et al.
Publicado: (2021)

Bioelectronics in the brain–gut axis: focus on inflammatory bowel disease (IBD)
por: Stakenborg, Nathalie, et al.
Publicado: (2021)

Awareness of adverse effects of Azathioprine in patients with Inflammatory Bowel Disease – more to be done?
por: Spence, Andrew David Roy, et al.
Publicado: (2014)

Management of iron deficiency anemia in inflammatory bowel disease – a practical approach
por: Stein, Jürgen, et al.
Publicado: (2013)

Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study
por: Fangbin, Zhang, et al.
Publicado: (2016)

Segmental colitis associated with diverticulosis: is it the coexistence of colonic diverticulosis and inflammatory bowel disease?
por: Schembri, John, et al.
Publicado: (2017)

Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1bulqegn4vm1rp6jfpae6n5eis